Language: 简体中文 English
Jiabin Guo
Jiabin Guo, PhD
associate professor
Evaluation and Research Centre for Toxicology, Center of Disease Control and Prevention, PLA

Dr. Jiabin Guo got his Ph.D in Pharmacology from the School of Basic Medicine, Peking University. He is currently an associate professor of toxicology at the Center for Disease Control and Prevention, PLA (formerly the 10th Institute, Academy of Military Medical Sciences). He was a visiting scholar at the University of California, Irvine during 2007 to 2009. He has published about 50 publications in toxicology over the past decade and got a number of awards such as LUSH Non-Animal Test Asia Outstanding Young Scholar Award, Excellent Young Worker of Chinese Pharmacological Society, Chinese Toxicology Society-Unilever Alternative Method Innovation Award, et al. He is serviced as the Secretary General of the Committee of Toxicity Testing and Alternative Methods, the Society of Chinese Environmental Mutagen Society, and a committee member of the Industrial Toxicology of the Chinese Society of Toxicology. He is a tutor of the Master of Public Health (MPH) of Peking University, a visiting professor of Jiangxi University of Traditional Chinese Medicine, and a reviewer of the National Natural Science Foundation of China, as well as the peer-reviewer of a number of scientific journals such as Food and Chemical Toxicology, Toxicology in Vitro, and International Journal of Cardiology.

In Vitro Alternatives in Drug Discovery and Safety Evaluation

Safety and efficacy are two key factors determining the success of the R&D of innovative drugs and drug withdrawal. Traditional drug toxicity testing and safety predictions are facing great challenges. In recent years, with the development and development of the 21st century toxicity test strategy (TT21C), drug toxicity test based on toxic mechanism has become an important development direction of drug discovery and safety evaluation. In the past decade since the release of TT21C by the US National Research Council, a group of new approach methods has been developed and applied in drug discovery and safety evaluation. In particular, the complete ban on animal testing for cosmetics in Europe and the Lautenberg Chemical Safety Act in the United States have provided strong incentives to develop alternative strategies, which also brings significant impacts on pharmaceutical industry. In facing the challenges of traditional animal-based toxicity testing methods, TT21C has been widely developed and applied in drug discovery and safety evaluation, with emphasis on using in vitro alternatives that formed human originated cell- and mechanisms-based testing strategies. A group of case study chemicals (including doxorubicin, diclofenac, troglitazone, phenoxyethanol, niacinamide and caffeine) was assessed using a panel human originated cell- based, high content imaging assays designed to detect effects on several different cell stress pathways including mitochondrial toxicity and oxidative stress. For materials where initial work indicates a potential for mitochondrial toxicity, higher tier investigations may be appropriate. In some cases, many different cell models are applied and compared such as human originated cell lines and hiPSC-derived cells and compared to both measured human systemic levels of tested drugs in patients undergoing treatment as well as systemic levels predicted from Physiologically Based Kinetic modelling. In silico modelling approaches have also been taken to describe the inter-relationship between the biomarkers tested. Our results indicate that a tiered approach integrated with in vitro alternatives and a mechanisms/pathways-based strategy can be incorporated into drug discovery and safety evaluation

  • DAYS
Key Dates
   Deadline for Submission of Abstract:
  October 31, 2018
   Notification of abstract acceptance:
   November 15, 2018